LAPPE RODNEY W 4

What Happened

• Rodney W. Lappe, a director of Design Therapeutics (DSGN), was granted a derivative award on 2026-06-09 covering 30,000 shares. The reported acquisition price is $0.00, so no cash was paid by the insider at grant. This filing reports an award (transaction code "A"), not a sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (appears filed within the standard 2-business-day window).
• Transaction type/code: Grant / Award (A); 30,000 shares; price reported $0.00; derivative security.
• Vesting: The award vests in equal monthly installments over 12 months beginning June 9, 2026, and in any case will be fully vested by the company’s next annual meeting of stockholders (footnote).
• Shares owned after the transaction: Not specified in the provided filing details.
• No indication of a sale, tax withholding, 10b5-1 plan, or late filing in this report.

Context

• This is a time‑based vesting award (derivative) to a director—common for board compensation. Because no shares were sold, there is no immediate liquidity event to interpret. As with all grants, the award represents compensation, not necessarily a direct signal of the insider’s view on near-term stock performance.